IRadimed Corp. IRMD

ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference. Iradimed’s CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 5th Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on Septemb

Kayne Anderson Rudnick’s chief market strategist, Julie Biel, says investors’ rush to own big AI names has left some great industrial and financial stocks underpriced.

IRADIMED CORPORATION recently reported past second-quarter 2026 results showing sales of US$20.47 million, slightly higher than a year earlier, alongside lower quarterly net income and earnings per share, while first-half 2026 sales and earnings modestly increased year over year. At the same time, the company issued revenue and earnings guidance for the third quarter and reaffirmed its full‑year 2026 outlook, while maintaining a regular US$0.20 per‑share quarterly dividend, underscoring...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

iRadimed Corp (IRMD) navigates a pivotal transition quarter with robust bookings for its next-generation MRI pump, offset by near-term margin pressure and flat revenue growth.

Moby summary of IRadimed Corporation's Q2 2026 earnings call

Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025.Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on August 28, 2026. ORLAN

Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark performed well during a speculative period for micro caps. Over the […]

ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.

Recent performance snapshot for IRADIMED (IRMD) IRADIMED (IRMD) has drawn investor attention after a period where the stock is up about 7% over the past month but down roughly 9% in the past 3 months, with a 1-year total return above 50%. See our latest analysis for IRADIMED. At a share price of $91.12, IRADIMED’s recent 1 day share price gain of 1.40% sits against a 7 day share price return that is slightly lower. Its 1 year total shareholder return of 52.01% and 5 year total shareholder...

Iradimed Corp (NASDAQ:IRMD) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. The stock has returned nearly 80% over the past year, and analysts see more upside potential in it. Iradimed reported its Q1 2026 results on May 1, and the results marked a strong start […]

ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors interested in meeting with Iradimed management during the conference may

In the past quarter ended March 31, 2026, IRADIMED CORPORATION reported first-quarter sales of US$21.98 million and net income of US$5.82 million, raised earnings per share versus a year earlier, reaffirmed its 2026 revenue and earnings outlook, and declared a regular US$0.20 quarterly dividend. The combination of year-over-year profit growth, maintained full-year guidance, and continued dividend payments highlights management’s confidence in the durability of IRADIMED’s MRI-compatible...